Literature DB >> 25780299

Corticosteroid therapy in ulcerative colitis: Clinical response and predictors.

Jin Li1, Fan Wang1, Hong-Jie Zhang1, Jian-Qiu Sheng1, Wen-Feng Yan1, Min-Xing Ma1, Ru-Ying Fan1, Fang Gu1, Chuan-Feng Li1, Da-Fan Chen1, Ping Zheng1, Yu-Pei Gu1, Qian Cao1, Hong Yang1, Jia-Ming Qian1, Pin-Jin Hu1, Bing Xia1.   

Abstract

AIM: To evaluate clinical response to initial corticosteroid (CS) treatment in Chinese ulcerative colitis patients (UC) and identify predictors of clinical response.
METHODS: Four hundred and twenty-three UC patients who were initially treated with oral or intravenous CS from 2007 to 2011 were retrospectively reviewed at eight inflammatory bowel disease centers in China, and 101 consecutive cases with one-year follow-up were analyzed further for clinical response and predictors. Short-term outcomes within one month were classified as primary response and primary non-response. Long-term outcomes within one year were classified as prolonged CS response, CS dependence and secondary non-response. CS refractoriness included primary and secondary non-response. Multivariate analyses were performed to identify predictors associated with clinical response.
RESULTS: Within one month, 95.0% and 5.0% of the cases were classified into primary response and non-response, respectively. Within one year, 41.6% of cases were assessed as prolonged CS response, while 49.5% as CS dependence and 4.0% as secondary non-response. The rate of CS refractoriness was 8.9%, while the cumulative rate of surgery was 6.9% within one year. After multivariate analysis of all the variables, tenesmus was found to be a negative predictor of CS dependence (OR = 0.336; 95%CI: 0.147-0.768; P = 0.013) and weight loss as a predictor of CS refractoriness (OR = 5.662; 95%CI: 1.111-28.857; P = 0.040). After one-month treatment, sustained high Sutherland score (≥ 6) also predicted CS dependence (OR = 2.347; 95%CI: 0.935-5.890; P = 0.014).
CONCLUSION: Tenesmus was a negative predictor of CS dependence, while weight loss and sustained high Sutherland score were strongly associated with poor CS response.

Entities:  

Keywords:  Clinical response; Corticosteroid; Predictor; Ulcerative colitis

Mesh:

Substances:

Year:  2015        PMID: 25780299      PMCID: PMC4356921          DOI: 10.3748/wjg.v21.i10.3005

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  33 in total

Review 1.  Progression of inflammatory bowel disease in China.

Authors:  Yu Fang Wang; Qin Ouyang; Ren Wei Hu
Journal:  J Dig Dis       Date:  2010-04       Impact factor: 2.325

2.  Infliximab for induction and maintenance therapy for ulcerative colitis.

Authors:  Alan C Moss; Richard J Farrell
Journal:  Gastroenterology       Date:  2006-11       Impact factor: 22.682

3.  A population-based study of the frequency of corticosteroid resistance and dependence in pediatric patients with Crohn's disease and ulcerative colitis.

Authors:  Jeanne Tung; Edward V Loftus; Deborah K Freese; Mounif El-Youssef; Alan R Zinsmeister; L Joseph Melton; W Scott Harmsen; William J Sandborn; William A Faubion
Journal:  Inflamm Bowel Dis       Date:  2006-12       Impact factor: 5.325

4.  Ulcerative colitis in China: retrospective analysis of 3100 hospitalized patients.

Authors:  Yufang Wang; Qin Ouyang
Journal:  J Gastroenterol Hepatol       Date:  2007-09       Impact factor: 4.029

Review 5.  The genetics of inflammatory bowel disease.

Authors:  Johan Van Limbergen; Richard K Russell; Elaine R Nimmo; Jack Satsangi
Journal:  Am J Gastroenterol       Date:  2007-09-25       Impact factor: 10.864

Review 6.  The genetics and immunopathogenesis of inflammatory bowel disease.

Authors:  Judy H Cho
Journal:  Nat Rev Immunol       Date:  2008-06       Impact factor: 53.106

7.  Clinical manifestations of inflammatory bowel disease: East and West differences.

Authors:  Yu Fang Wang; Hu Zhang; Qin Ouyang
Journal:  J Dig Dis       Date:  2007-08       Impact factor: 2.325

8.  Predictors of corticosteroid-dependent and corticosteroid-refractory inflammatory bowel disease: analysis of a Chinese cohort study.

Authors:  D K L Chow; J J Y Sung; K K F Tsoi; V W S Wong; J C Y Wu; R W L Leong; F K L Chan
Journal:  Aliment Pharmacol Ther       Date:  2009-01-20       Impact factor: 8.171

9.  OCTN and CARD15 gene polymorphism in Chinese patients with inflammatory bowel disease.

Authors:  Mei Li; Xiang Gao; Chang-Cun Guo; Kai-Chun Wu; Xin Zhang; Pin-Jin Hu
Journal:  World J Gastroenterol       Date:  2008-08-21       Impact factor: 5.742

10.  Laboratory values for children with newly diagnosed inflammatory bowel disease.

Authors:  David R Mack; Christine Langton; James Markowitz; Neal LeLeiko; Anne Griffiths; Athos Bousvaros; Jonathan Evans; Subra Kugathasan; Anthony Otley; Mariann Pfefferkorn; Joel Rosh; Adam Mezoff; Susan Moyer; Maria Oliva-Hemker; Robert Rothbaum; Robert Wyllie; J Fernando delRosario; David Keljo; Trudy Lerer; Jeffrey Hyams
Journal:  Pediatrics       Date:  2007-06       Impact factor: 7.124

View more
  10 in total

1.  Pharmacological and metabolomic profiles of Musa acuminata wastes as a new potential source of anti-ulcerative colitis agents.

Authors:  Mona A Mohammed; Bassant M M Ibrahim; Yasmin Abdel-Latif; Azza H Hassan; Mohamed A El Raey; Emad M Hassan; Souad E El-Gengaihi
Journal:  Sci Rep       Date:  2022-06-22       Impact factor: 4.996

Review 2.  Inflammatory Bowel Disease Treatments and Predictive Biomarkers of Therapeutic Response.

Authors:  Duaa Ahmed Elhag; Manoj Kumar; Marwa Saadaoui; Anthony K Akobeng; Fatma Al-Mudahka; Mamoun Elawad; Souhaila Al Khodor
Journal:  Int J Mol Sci       Date:  2022-06-23       Impact factor: 6.208

Review 3.  Treatment of Inflammatory Bowel Disease: A Comprehensive Review.

Authors:  Zhaobei Cai; Shu Wang; Jiannan Li
Journal:  Front Med (Lausanne)       Date:  2021-12-20

4.  Bortezomib protects against dextran sulfate sodium‑induced ulcerative colitis in mice.

Authors:  Li-Hong Hu; Yu-Jing Fan; Qing Li; Jing-Ming Guan; Bo Qu; Feng-Hua Pei; Bing-Rong Liu
Journal:  Mol Med Rep       Date:  2017-04-27       Impact factor: 2.952

5.  Epidemiological and clinical aspects of ulcerative colitis in west of Iran: a cross sectional study.

Authors:  Koroush Ghanadi; Javad Valizadeh; Afshin Hasanvand
Journal:  Springerplus       Date:  2016-09-15

Review 6.  Beverage consumption and risk of ulcerative colitis: Systematic review and meta-analysis of epidemiological studies.

Authors:  Jia-Yan Nie; Qiu Zhao
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

7.  Magnolol, a Natural Polyphenol, Attenuates Dextran Sulfate Sodium-Induced Colitis in Mice.

Authors:  Ling Zhao; Hai-Tao Xiao; Huai-Xue Mu; Tao Huang; Ze-Si Lin; Linda L D Zhong; Guang-Zhi Zeng; Bao-Min Fan; Cheng-Yuan Lin; Zhao-Xiang Bian
Journal:  Molecules       Date:  2017-07-20       Impact factor: 4.411

8.  The Use of Curcumin as a Complementary Therapy in Ulcerative Colitis: A Systematic Review of Randomized Controlled Clinical Trials.

Authors:  Mariana Roque Coelho; Marcela Diogo Romi; Daniele Masterson Tavares Pereira Ferreira; Cyrla Zaltman; Marcia Soares-Mota
Journal:  Nutrients       Date:  2020-07-31       Impact factor: 5.717

9.  Altered profiles of fecal bile acids correlate with gut microbiota and inflammatory responses in patients with ulcerative colitis.

Authors:  Zhen-Huan Yang; Fang Liu; Xiao-Ran Zhu; Fei-Ya Suo; Zi-Jun Jia; Shu-Kun Yao
Journal:  World J Gastroenterol       Date:  2021-06-28       Impact factor: 5.742

10.  The effectiveness and safety of curcumin as a complementary therapy in inflammatory bowel disease: A protocol of systematic review and meta-analysis.

Authors:  Zhenhuan Yang; Wenjing Liu; Xuefeng Zhou; Xiaoran Zhu; Feiya Suo; Shukun Yao
Journal:  Medicine (Baltimore)       Date:  2020-10-23       Impact factor: 1.817

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.